Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

This experimental pill helped people lose about 16% of their body weight after about a year of treatment ...

DYNAMIKA™ delivers SOC 2 Type II–certified, AI‑driven imaging workflows, giving pharma and biotech secure, compliant ...

Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate. The reprioritization is meant to ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people ...

And thanks for Stifel for having us here this afternoon. So yes, if I look at 2026 as we exited the prior year, we're entering this year, with a great deal of enterprise-wide momentum, and this comes ...